×
InMode reported third-quarter 2026 revenue of $92.1 million, roughly flat to down about 1% from $93.2 million a year earlier and in line with its pre-announced range of $91.8 million to $92.0 million. Non-GAAP (adjusted) diluted EPS came in at $0.37, topping the consensus estimate of roughly $0.32, while GAAP diluted EPS fell to $0.32 from $0.34 a year ago.
AVR is the ticker for Anteris Technologies Global Corp., a development-stage medical device company focused on structural heart disease. The company's lead product is the DurAVR® Transcatheter Heart Valve (THV) System, a "biomimetic" aortic valve designed to treat severe aortic stenosis.
INMD is the Nasdaq-listed ticker for InMode Ltd., an Israel-based medical device maker specializing in energy-based aesthetic and medical treatments. The company's products use proprietary radio frequency (RF) technology for minimally invasive, non-invasive, and hands-free procedures across plastic surgery, dermatology, gynecology, and ophthalmology.
The $2.50 price target is a fallback objective tied to public discussion of the reverse split and technical recovery levels, not an analyst consensus. With the shares recently trading near $1.80, reaching $2.50 would require a roughly 39% gain, a substantial move for a micro-cap in a downtrend.
The central target of $20 is the arithmetic mean of the two current analyst price targets on file: $10 and $30. With shares trading near $2.52 , reaching $20 would require a gain of roughly 690% , an extremely large move by any standard.
The central target of $6 is the most recent verifiable analyst price target from Maxim Group's Anthony Vendetti, who maintained a Buy rating and cut his target from $42 in October 2026. Because AMIX has effectively only one current, attributable target after its 1-for-21 reverse stock split, a meaningful multi-analyst average does not exist. With the latest verified price near $1.70, reaching $6 would require a gain of roughly 250% or more, which is a very large move for a development-stage medical device company.
The $8 target in this article is not an analyst consensus; it is a fallback reference point derived from public valuation discussion and the stock's own recent trading history. Aethlon Medical has extremely thin analyst coverage. The only verifiable current price target is H.C. Wainwright's $1.50 Hold target (reiterated September 18, 2026), which sits below the market price.
The $3.00 objective used in this analysis is a technical, round-number milestone drawn from public chart discussion, not an official analyst consensus, because INBS lacks a credible multi-analyst price target. At roughly $2.10, reaching $3.00 would require a gain of about 43%, a substantial move even for a highly volatile micro-cap.
The central price target of $5.40 is the arithmetic mean of four verified, current analyst price targets reviewed for Microbot Medical Inc. (MBOT) . With shares trading near $1.05 , reaching $5.40 would require a gain of roughly 415% — a very large move.
The central price target is $14 , the arithmetic mean of verified analyst targets from Cantor Fitzgerald ($15), TD Cowen ($15), Wells Fargo ($16), and Barclays ($10). At a recent price near $6.20 , Anteris Technologies Global Corp. (AVR) would need to gain roughly 126% to reach $14 — a very large move for any equity.
The central target of $16.50 is the arithmetic mean of four verified analyst price targets, which range from $15 to $19. With the stock trading near $13.30 , reaching $16.50 implies upside of roughly 24% — a substantial move, not a modest one.
Nyxoah (NYXH) shares declined roughly 32% over the last 30 days, falling from about $1.31 to near $0.89. The selloff was driven primarily by a cut to full-year 2026 revenue guidance, announced alongside preliminary third-quarter results.
The central target of $10 is the arithmetic mean of five verified analyst price targets, which average $9.80 and round to $10. At a latest verified price near $2.85, reaching $10 implies roughly 251% upside — a very large move by any standard.
TriSalus Life Sciences (TLSI) shares have fallen roughly 30% over the trailing 30 days, extending a multi-month decline that has taken the stock from the low-$5 range to near $2.85. The sharpest drop followed third-quarter 2026 results, in which revenue and earnings missed consensus and full-year guidance was cut for the third consecutive quarter.
Perspective Therapeutics (CATX) shares declined roughly 67% over the trailing 30 days, extending a steeper multi-month downtrend. The selloff was triggered by an October 2026 Phase 1/2a data readout for its lead candidate, VMT-α-NET, which investors viewed as mixed.
The central $10 target reflects an average of verified analyst price targets on Perspective Therapeutics, Inc. (CATX) , a clinical-stage radiopharmaceutical developer, rather than a published consensus. Analyst targets reviewed span a very wide range — roughly $4 to $15 — underscoring genuine disagreement about the company's lead-212 platform and pipeline timeline.
TXG climbed to $65.37 from a $62.90 prior close, a gain of +3.93%, during regular trading hours. No verified news or fundamental catalyst found for today's move — it is likely a technical rebound from last week's oversold, post-earnings selloff.
LMRI jumped +14.22% to roughly $15.90 from its prior close of $13.92 during early regular trading on November 11. The move followed Tuesday's after-hours Q3 report: adjusted EPS of $0.26 beat the ~$0.18 consensus, revenue edged past estimates, and full-year adjusted EPS guidance was raised to $0.86–$0.90.
BRKRP slid -6.30% during regular market hours, falling from a previous close of $484.69 to $454.17. No verified news or fundamental catalyst found. The drop likely reflects thin, low-liquidity trading in this preferred issue — only a few hundred shares changed hands — consistent with its roughly ±2.6% average daily move and its habit of swinging 6% or more on several recent sessions.
ISRG (Intuitive Surgical) is a large-cap, profitable leader in robotic-assisted surgery, while PRCT (PROCEPT BioRobotics) is a smaller, high-growth but still loss-making player focused on urology. Both companies delivered solid revenue growth in recent quarters, but ISRG's scale and recurring-revenue model contrast sharply with PRCT's early-stage profitability and cash-burn profile.